Ferreira JP, et al. - Given the predictive value of the 6-minute walk test (6MWT) in patients with heart failure (HF) for morbidity and mortality, researchers reported on the findings of large multicenter cohorts assessing the predictive value of baseline and changing walk distance. A 6MWT was performed at baseline (n=1,714) and 9 months (n=1,520) in BIOSTAT-CHF study. Older age, female sex, higher heart rate, New York Heart Association class III/IV, orthopnea, ischemic heart disease, a previous stroke, current malignancy, and higher N-terminal pro-B-type natriuretic peptide were noted to be independent predictors of a shorter 6MWT distance. They noted an association of both the 6MWT distance at baseline and a decline in walking distance, with worse prognosis; however, these did not improve the prognostic models. No modification was noted in the 6MWT distance by treatment up-titration, suggesting a limited utility of 6MWT distance for assessing the benefits of pharmacologic treatment up-titration.